Conference Proceedings: “Progress in Thyroid-Associated Ophthalmopathy”

References

• Hiromatsu Y., Tanaka K., Ishisaka N., Kamachi J., Kuroki T., Hoshino T., Inoue Y., Wall J. R., Nonaka K. Human histocompatibility leukocyte antigen-Dr and heat shock protein-70 expression in eye muscle tissue in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 1994; 80: 685–691
   Web of Science ®Google Scholar
• Bahn R. S. The fibroblast is the target cell in the connective tissue manifestations of Graves' disease. Intl. Arch. of Allerg. & Immunol. 1995; 106: 213–218
   PubMed Web of Science ®Google Scholar
• Kiljanski J., Nebes V., Wall J. R. The ocular muscle cell is a target of the immune system in endocrine ophthalmopathy. Pro. Intl. Arch. Allergy Immunol. 1995; 106: 204–212
   PubMed Web of Science ®Google Scholar
• Wall J. R., Kiljanski J., Nebes V., Stachura I., Kennerdell J. S. Should Graves' disease be considered a collagen disorder of the thyroid, skeletal muscle and connective tissue?. Hor. Metab. Res.
   Web of Science ®Google Scholar
• Smith T. J., Wang H. S., Evans C. H. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured orbital fibroblasts. American J. Physiol. Cell Physiol. 1995; 268: C3882–C388
   Web of Science ®Google Scholar
• Hogg M. G., Evans C. H., Smith T. L. Leukoregulin induces plasminogen activator inhibitor type-1 in human orbital fibroblasts. American J. Physiol. Cell Physiol. 1995; 269: C359–C366
   Web of Science ®Google Scholar
• Wall J. R., Nebes V., Kiljanski J., Bernard N., Barsouk A. Generalized nature of the immunologic abnormalities in Graves' disease; pathogenesis of the extrathyroidal manifestations. Orbit, (In press)
   Google Scholar
• Arnold K., Metcalfe R., Weetman A. R. IgA class fibroblast antibodies in patients with Graves' disease and pretibial myxedema. J. Clin. Endocrinol Metab.
   Google Scholar
• Hiromatsu Y., Fukazawa H., How J., Wall J. R. Antibody-dependent cell-mediated cytotoxicity against human eye muscle cells and orbital fibroblasts in Graves' ophthalmopathy—roles of Class II MHC antigen expression and gamma-interferon actions on effector cells. Clin. Exp. Immunol. 1987; 70: 593–603
   PubMed Web of Science ®Google Scholar
• Salvi M., Miller A., Wall J. R. Human orbital tissue and thyroid membranes express a 64 kDa protein which is recognized by autoantibodies in the serum of patients with thyroid-associated ophthalmopathy. FEBS Letters 1988; 232: 135–139
   PubMed Web of Science ®Google Scholar
• Heufelder A. E., Dutton C. M., Sarkar G., Donovan K. A., Bahn R. S. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid 1993; 3: 297–300
   PubMed Web of Science ®Google Scholar
• Endo T., Ohta K., Haraguchi K., Onaya T. Cloning and functional expression of a thyrotropin receptor cDNA from fat cells. J. Biol. Chem. 1995; 270: 10833–10837
   PubMed Web of Science ®Google Scholar
• Franklyn J. A. Graves' ophthalmopathy and the TSH receptor. Lancet 1993; 342: 318–319
   PubMed Web of Science ®Google Scholar
• Davies T. F. The thyrotropin receptors spread themselves around. J. Clin. Endocrinol Metabol 1994; 79: 1232–1233
   PubMed Web of Science ®Google Scholar
• Salvi M., De Chiara F., Gardini E., Minelli R., Bianconi L., Alnovi A., Ricci R., Neri F., Tosi C., Roti E. Echocardiographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease. Acta Endocrinol (Copenh) 1994; 131: 113–119
   Google Scholar
• Dudgeon L. S., Urquhart A. L. Lymphorrhages in the muscle in exophthalmic goiter. Brain 1975; 49: 182–186
   Google Scholar
• Burch H. B., Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine. Reviews 1993; 14: 747–793
   PubMed Web of Science ®Google Scholar
• Barsouk A., Fraiture Peele K. A., Stolarski C., Nebes V., Hayes M., Kennerdell J., Wall J. R. Increased managanese superoxide dismutase activity in lacrimal secretions (tears) from patients with thyroid-associated ophthalmopathy; correlation with eye muscle dysfunction. Proc. 11th International Thyroid Congress, TorontoCanada, September, 11–151995, (abstract)
   Google Scholar
• Dong Q., Ludgate M., Vassart V. Cloning and sequencing of a novel 64 kDa autoantigen recognized by patients with autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 1991; 92: 1375–1381
   Google Scholar
• Hiromatsu Y., Sato M., Tanaka K., Shoji S., Nonaka K., Chinami M., Fukazawa H. Significance of anti-eye muscle antibody in patients with thyroid-associated ophthalmopathy by quantitative Western blot. Autoimmunity 1993; 14: 1–8
   PubMed Web of Science ®Google Scholar
• Dakovska L., Vulkova H., Kovatchena R., Todorova S., Iozanov B. A., Tanassova I., Assianova N., Ivanova R., Sarafova A. Anti-eye muscle antibodies in patients with thyroid-associated ophthalmopathy (TAO). Proc. Annual Balkan Congress of Endocrinology, Bursa, Turkey. 1995, (abstract)
   Google Scholar
• Wengrowicz S., Puig-Domingo M., Soldevial J., de Leiva A. Prevalences of antibodies reactive with pig eye muscle membrane antigens in patients with thyroid-associated ophthalmopathy. Proc 11th. International Thyroid Congress, TorontoCanada, September, 11–151995, (Abstract)
   Google Scholar
• Salvi M., Bernard N., Miller A., Zhang Z. G., Gardini E., Wall J. R. Prevalence of antibodies reactive with a 64 kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy. Thyroid 1991; 1: 207–213
   PubMedGoogle Scholar
• Chang T. G., Chang T. J., Huang Y. S., Hua K. M., Su R. J., Kao S. C.S. Identification of autoantigen recognized by autoimmune ophthalmopathy sera with immunoblotting correlated with orbital computed tomography. Clin. Immunol. Immunopath. 1992; 65: 161–166
   PubMedGoogle Scholar
• Arnold K., Tandon N., Macintosh R. S., Ludgate R. M., Weetman A. P. T cell responses to orbital antigens in thyroid-associated ophthalmopathy. Clin. Exp. Immunol. 1994; 96: 329–334
   PubMed Web of Science ®Google Scholar
• Stover C., Otto E., Beyer J., Kahaly G. Cellular immunity and retrobular fibroblasts in Graves' ophthalmopathy. Thyroid 1994; 4: 161–165
   PubMed Web of Science ®Google Scholar
• De Groot L., Gorman C., Pinchera A., Bartelena L., Marcocci C., Wiersinga A., Prummel M. F. Therapeutic controversies. Radiation and Graves' ophthalmopathy. J. Clin. Enocrinol. Metab. 1995; 80: 339–349
   PubMed Web of Science ®Google Scholar
• Tallstedt L., Lundell G., Torring O., Wallin G., Ljunggrenn J.-G., Blomgren H., Taube A. The Thyroid study Group. Occurrence of ophthalmopathy after treatment of Graves' hyperthyroidism. N. Engl. J. Med. 1995; 326: 1733–1738
   Google Scholar
• Bartelena L., Martino E., Marrococci C., Pinchera A. More on smoking habits and Graves' ophthalmopathy. J. Endocrinol. Invest. 1989; 12: 733–737
   PubMed Web of Science ®Google Scholar
• Cooper D. S. Tobacco and Graves' disease. Smoking gun or smoke and mirrors. JAMA 1993; 269: 518–519, Editorial
   PubMed Web of Science ®Google Scholar
• Bartley G. B. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted county, Minnesota. Dev. Ophthalmol. 1989; 20: 159–168
   PubMedGoogle Scholar
• Committees of Regional Thyroid Associations. Classification of eye changes of Graves' disease. Thyroid 1992; 2: 235–236
   PubMed Web of Science ®Google Scholar
• Prummel M., Wiersinga W. Medical management of Graves' ophthalmopathy Thyroid 1995; 5: 231–234
   PubMed Web of Science ®Google Scholar
• Petersen I. A., Kriss J. P., McDougall I. R., Donaldson S. S. Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int. J. Radial. Oncol. Biol. Phys. 1990; 19: 259–264
   Web of Science ®Google Scholar
• Nagayama Y., Izumi M., Kirijama T., Yokoyama N., Morito S., Kakezona F., Ohtakara S., Morimoto I., Okamoto S., Nagataki S. Treatment of Graves' ophthalmopathy with high dose intravenous methylprednisolone therapy. Acta. Endocrinol. 1987; 116: 513–518
   PubMedGoogle Scholar
• Antonelli A., Saracino A., Alberti B., Canapicchi R., Cartei F., Lepri A., Laddaga M., Baschieri L. High-dose intravenous immunoglobulin treatment in Graves' Ophthalmopathy. Acta Endocrinologka. 1992; 126: 13–23
   PubMed Web of Science ®Google Scholar
• Kennerdell J. S., Baron E. M., Wall J. R., Tyutyunikov A., Genovese C. Dysthyroid orbitopathy. Mosby. Year Book 1995, (In press)
   Google Scholar
• Garrity J., Fatourechi V., Bergstalh E. J., Bartley G. B., Beatty C. W., De Santo L. W., Gorman C. Results of transnasal orbital decompression in 428 patients with severe Graves' ophthalmopathy. Am. J. Ophthalmol., 116: 533–547
   PubMed Web of Science ®Google Scholar
• Kahaly G., Diaz M., Just M., Beyer J., Lieb W. Role of Octreoscan and correlation with MR imaging in Graves' Ophthalmopathy. Thyroid 1993; 5: 107–111
   Web of Science ®Google Scholar
• Portolano S., Seto P., Chazenbalk G. D., Nagayama Y., McLachlan S., Rapoport B. A human fab fragment specific for thyroid peroxidase generated by cloning thyroid lymphocyte-derived immunoglobulin genes in a bacteriophage lambda library. Biochem. Biophys. Res. Comm. 1991; 179: 372–379
   PubMed Web of Science ®Google Scholar
• Paschke R., Metcalfe A., Alcalde L., Vassart G., Weetman A., Ludgate M. Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissue. J. Clin. Endocrinol. Metabol. 1994; 79: 1234–1238
   PubMed Web of Science ®Google Scholar